ATE428790T1 - Verbessertes system zur regulation der transgenexpression - Google Patents

Verbessertes system zur regulation der transgenexpression

Info

Publication number
ATE428790T1
ATE428790T1 AT01977218T AT01977218T ATE428790T1 AT E428790 T1 ATE428790 T1 AT E428790T1 AT 01977218 T AT01977218 T AT 01977218T AT 01977218 T AT01977218 T AT 01977218T AT E428790 T1 ATE428790 T1 AT E428790T1
Authority
AT
Austria
Prior art keywords
improved system
transgene expression
regulating transgene
regulating
inducer
Prior art date
Application number
AT01977218T
Other languages
English (en)
Inventor
Ronald Abruzzese
Vidya Mehta
Jeffrey Nordstrom
Jason G Fewell
Original Assignee
Genetronics Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc, Baylor College Medicine filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE428790T1 publication Critical patent/ATE428790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mushroom Cultivation (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Paper (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Eye Examination Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01977218T 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression ATE428790T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23503000P 2000-09-25 2000-09-25
US26078101P 2001-01-10 2001-01-10
US27828101P 2001-03-23 2001-03-23
PCT/US2001/030305 WO2002024899A2 (en) 2000-09-25 2001-09-25 Improved system for regulation of transgene expression

Publications (1)

Publication Number Publication Date
ATE428790T1 true ATE428790T1 (de) 2009-05-15

Family

ID=27398677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977218T ATE428790T1 (de) 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression

Country Status (7)

Country Link
US (1) US7579326B2 (de)
EP (1) EP1326969B1 (de)
AT (1) ATE428790T1 (de)
AU (1) AU2001296354A1 (de)
CA (1) CA2423093C (de)
DE (1) DE60138404D1 (de)
WO (1) WO2002024899A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US9453219B2 (en) * 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
CA2580515C (en) * 2004-10-04 2017-05-02 National Research Council Of Canada Expression system, components thereof and methods of use
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
CN101238214A (zh) * 2005-05-19 2008-08-06 拜尔先灵制药股份公司 使用改进的调节表达系统治疗疾病
AR053284A1 (es) * 2005-05-19 2007-04-25 Schering Ag Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
WO2007134906A1 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
EP2285832B1 (de) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antikörper und herstellungsverfahren dafür
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
CN102575227A (zh) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
PE20181208A1 (es) * 2015-06-26 2018-07-23 Bayer Animal Health Gmbh Metodos de modulacion de moleculas de vigilancia de adn citosolicas
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US20170198363A1 (en) * 2015-12-28 2017-07-13 Colorado State University Research Foundation Compositions and methods for detection of small molecules
EP3411483B1 (de) * 2016-02-05 2022-07-06 PolyGene AG Glucocorticoid-basiertes genregulationssystem
EP3235516B1 (de) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulierbarer adeno-assoziierter virus (aav)-vektor
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11780902B1 (en) 2018-07-20 2023-10-10 Colorado State University Research Foundation Receptor/histidine kinase fusion constructs and uses thereof
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (de) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur behandlung von t-zell-erschöpfung
EP4110931A4 (de) * 2020-02-25 2024-03-27 University of Massachusetts Induzierbares single-aav-system und verwendungen davon

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS62171696A (ja) 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1990014356A1 (en) 1989-05-26 1990-11-29 The Salk Institute For Biological Studies Dominant negative members of the steroid/thyroid superfamily of receptors
WO1990007517A1 (en) 1988-12-23 1990-07-12 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US6416998B1 (en) * 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
CA2269642A1 (en) * 1996-10-29 1998-05-07 Valentis, Inc. Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
GB9718591D0 (en) * 1997-09-03 1997-11-05 Zeneca Ltd Methods
JP2001526243A (ja) * 1997-12-23 2001-12-18 セル ジェネシス インコーポレイテッド 複数のアデノ随伴ウイルスベクターを使用する、複数の遺伝子の細胞への送達
GB9817660D0 (en) 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
AU1523900A (en) * 1998-11-20 2000-06-13 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use

Also Published As

Publication number Publication date
AU2001296354A1 (en) 2002-04-02
WO2002024899A3 (en) 2002-12-12
CA2423093A1 (en) 2002-03-28
US7579326B2 (en) 2009-08-25
DE60138404D1 (de) 2009-05-28
US20030220286A1 (en) 2003-11-27
WO2002024899A2 (en) 2002-03-28
EP1326969A2 (de) 2003-07-16
CA2423093C (en) 2013-09-17
EP1326969B1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
ATE428790T1 (de) Verbessertes system zur regulation der transgenexpression
ATE439440T1 (de) Sirna-vermitteltes gen-silencing von alpha- synuklein
DK1334200T3 (da) Multipelt inducerbart genreguleringssystem
DK1354034T3 (da) Transgene transchromosomale gnavere til fremstilling af humane antistoffer
DE60232245D1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
HRP20050705B1 (hr) Ekspresijski vektor koji sadrži promotor mcmv ie2
BRPI0413024A (pt) sistema de expressão de gene de inseto, promotor, vetor, inseto e, método para estabelecer compatibilidade de um promotor com uma espécie
DE602004030315D1 (de) Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
DE50210608D1 (de) Vorrichtung zur kontrolle von material
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
ATE543502T1 (de) Allomon-abstossungsmittel zur kontrolle von arachnidae
DE60128830D1 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
DK1210446T3 (da) Modificeret ubiquitin-regulatorisk system
EP1642969A4 (de) Fluoreszenzprotein und pigmentprotein
FR2827169B1 (fr) Durcisseur pour les ongles
ATE334592T1 (de) Biologische bekämpfung von nematoden
DK1368480T3 (da) Fremgangsmåde til ændring af genomet i grampositive bakterier ved hjælp af et nyt konditionalt negativt dominant markörgen
ATE273394T1 (de) Wirts-vektor-systeme zur phosphatregulierten überproduktion von polypeptiden in bacillus
ATE335087T1 (de) Globaler regulator, verwendet zur erhöhung der synthese von aromatischen substanzen
DK1082449T3 (da) Fremgangsmåder til stereoselektiv fremstilling af substituerede cyclohexylcyanhydriner
ATE307201T1 (de) Srcr domäne-enthaltendes protein
DK1507009T3 (da) Gen-silencing vektor og gen-silencing fremgangsmåde til anvendelse heraf
ATE454401T1 (de) Il-18bp promoter herstellung und verwendung
DK1089975T3 (da) Fremgangsmåde til fremstilling af substituerede pyridincarboxylsyrer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties